YU24201A - Aerosolne čestice otporne na porast higroskopnosti - Google Patents

Aerosolne čestice otporne na porast higroskopnosti

Info

Publication number
YU24201A
YU24201A YU24201A YU24201A YU24201A YU 24201 A YU24201 A YU 24201A YU 24201 A YU24201 A YU 24201A YU 24201 A YU24201 A YU 24201A YU 24201 A YU24201 A YU 24201A
Authority
YU
Yugoslavia
Prior art keywords
dry powder
powder particles
hygroscopic growth
particles resistant
growth
Prior art date
Application number
YU24201A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Andrew Clark
Mei-Chang Kuo
Cecily Lalor
Barry John Aldous
Original Assignee
Inhale Therapeutic Systems Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Systems Inc. filed Critical Inhale Therapeutic Systems Inc.
Publication of YU24201A publication Critical patent/YU24201A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
YU24201A 1998-09-14 1999-09-13 Aerosolne čestice otporne na porast higroskopnosti YU24201A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
YU24201A true YU24201A (sh) 2003-08-29

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
YU24201A YU24201A (sh) 1998-09-14 1999-09-13 Aerosolne čestice otporne na porast higroskopnosti

Country Status (44)

Country Link
EP (1) EP1117442A1 (fr)
JP (1) JP2002524535A (fr)
KR (1) KR20010075063A (fr)
CN (1) CN1317977A (fr)
AP (1) AP1374A (fr)
AR (1) AR022090A1 (fr)
AU (1) AU753014B2 (fr)
BG (1) BG105430A (fr)
BR (1) BR9913722A (fr)
CA (1) CA2343920A1 (fr)
CO (1) CO5130023A1 (fr)
CZ (1) CZ2001829A3 (fr)
DZ (1) DZ2892A1 (fr)
EA (1) EA003476B1 (fr)
EE (1) EE200100151A (fr)
GE (1) GEP20043257B (fr)
GT (1) GT199900156A (fr)
HK (1) HK1042231A1 (fr)
HN (1) HN1999000159A (fr)
HR (1) HRP20010189A2 (fr)
HU (1) HUP0103837A3 (fr)
ID (1) ID28845A (fr)
IL (2) IL141562A0 (fr)
IS (1) IS5878A (fr)
LT (1) LT4897B (fr)
LV (1) LV12658B (fr)
MA (1) MA25590A1 (fr)
MY (1) MY129282A (fr)
NO (1) NO20011251L (fr)
NZ (1) NZ510168A (fr)
OA (1) OA11781A (fr)
PA (1) PA8481901A1 (fr)
PE (1) PE20001061A1 (fr)
PL (1) PL195574B1 (fr)
SA (1) SA99200718B1 (fr)
SK (1) SK3442001A3 (fr)
TN (1) TNSN99173A1 (fr)
TR (1) TR200101182T2 (fr)
TW (1) TWI226248B (fr)
UA (1) UA76085C2 (fr)
UY (1) UY25711A1 (fr)
WO (1) WO2000015262A1 (fr)
YU (1) YU24201A (fr)
ZA (1) ZA200101995B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1185248B1 (fr) 1999-06-09 2012-05-02 Robert E. Sievers Nebulisation et sechage de bulles assiste par un fluide supercritique
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
CA2446904A1 (fr) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Administration d'esters medicamenteux par inhalation
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
JP2005518453A (ja) 2002-02-25 2005-06-23 ディフュージョン・ファーマシューティカルズ・エルエルシー 二極性トランスカロテノイド塩およびそれらの使用
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
CA2491129A1 (fr) * 2002-07-03 2004-01-15 Brigham And Women's Hospital, Inc. Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
EP1575563B1 (fr) * 2002-12-19 2007-02-14 Pharmacia Corporation Formulation a caractere non-hygroscopique comprenant un principe actif hydroscopique
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2007534693A (ja) * 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤
AU2006229688B2 (en) * 2005-02-24 2012-07-26 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1857114A1 (fr) * 2005-03-09 2007-11-21 Ono Pharmaceutical Co., Ltd. Particule et preparation la contenant
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PT2335707E (pt) 2005-10-26 2015-09-10 Cydex Pharmaceuticals Inc Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
EP2095812A4 (fr) * 2006-10-25 2011-07-13 Dainippon Sumitomo Pharma Co Préparation granulaire non agglutinante
EP1925295A1 (fr) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Formule de poudre stable contenant un nouveau anticholinergique
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
CA2703946A1 (fr) 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc Nouvelle classe d'agents therapeutiques qui ameliorent la diffusion des petites molecules
TR201802619T4 (tr) * 2009-05-20 2018-03-21 Aeras Kararlı, sprey ile kurutulmuş, immunojen, viral bileşimler.
AU2010263245A1 (en) 2009-06-22 2012-01-19 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
CA2801292C (fr) 2010-06-02 2019-01-22 Diffusion Pharmaceuticals Llc Formes pharmaceutiques orales a base de carotenoides trans bipolaires
CA2866230C (fr) 2012-05-03 2020-08-18 Janssen R&D Ireland Formulations d'acide polyinosinique-polycytidylique (poly (i:c)) pour le traitement d'infections du tractus respiratoire superieur
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
WO2015042352A1 (fr) * 2013-09-20 2015-03-26 Virginia Commonwealth University Administration de particules à l'aide d'excipients hygroscopiques
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
JP7032320B2 (ja) 2016-03-24 2022-03-08 ディフュージョン・ファーマシューティカルズ・エルエルシー 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
CA2115065C (fr) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Poudre particulaire ultrafine pour inhalation et methode de production
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
PT954282E (pt) * 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
IL141562A (en) 2007-07-24
NO20011251D0 (no) 2001-03-13
AU753014B2 (en) 2002-10-03
OA11781A (en) 2005-07-26
TWI226248B (en) 2005-01-11
ID28845A (id) 2001-07-05
HRP20010189A2 (en) 2005-04-30
PL346768A1 (en) 2002-02-25
SA99200718B1 (ar) 2006-11-04
LV12658A (lv) 2001-05-20
AU6039799A (en) 2000-04-03
CA2343920A1 (fr) 2000-03-23
GEP20043257B (en) 2004-06-25
EE200100151A (et) 2002-06-17
CO5130023A1 (es) 2002-02-27
EA200100300A1 (ru) 2001-10-22
AR022090A1 (es) 2002-09-04
TR200101182T2 (tr) 2001-09-21
EP1117442A1 (fr) 2001-07-25
IS5878A (is) 2001-03-05
PA8481901A1 (es) 2002-04-25
AP1374A (en) 2005-02-28
LT2001021A (en) 2001-11-26
UA76085C2 (en) 2006-07-17
JP2002524535A (ja) 2002-08-06
SK3442001A3 (en) 2001-11-06
HK1042231A1 (zh) 2002-08-09
AP2001002093A0 (en) 2001-03-31
PL195574B1 (pl) 2007-10-31
HUP0103837A2 (hu) 2002-05-29
GT199900156A (es) 2001-03-07
MY129282A (en) 2007-03-30
HN1999000159A (es) 1999-11-11
LT4897B (lt) 2002-02-25
MA25590A1 (fr) 2002-12-31
IL141562A0 (en) 2002-03-10
DZ2892A1 (fr) 2003-12-15
CN1317977A (zh) 2001-10-17
WO2000015262A1 (fr) 2000-03-23
TNSN99173A1 (fr) 2005-11-10
NO20011251L (no) 2001-04-17
PE20001061A1 (es) 2000-10-08
EA003476B1 (ru) 2003-06-26
UY25711A1 (es) 1999-11-17
HUP0103837A3 (en) 2002-11-28
KR20010075063A (ko) 2001-08-09
BG105430A (en) 2001-12-29
ZA200101995B (en) 2002-03-11
NZ510168A (en) 2003-09-26
BR9913722A (pt) 2001-05-29
LV12658B (lv) 2001-09-20
CZ2001829A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
MY129282A (en) Aerosolizable particles resistant to hygroscopic growth
NZ511527A (en) Dry powder for inhalation
MY129112A (en) Flow resistance modulated aerosolized active agent delivery
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
MX9702357A (es) Microparticulas secadas por aspersion como vehiculos terapeuticos.
GB1484781A (en) Compositions for dental treatment
IS5108A (is) Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, aðferð við að framleiða lyfjablönduna og notkun hennar
CA2412561A1 (fr) Distribution hautement efficace d'une grande quantite d'aerosol therapeutique
HU9201521D0 (en) Stimulating unit containing nicotine
NZ333724A (en) Enhancing lean tissue mass and bone mineral content by the administration of calcium compositions
IS5110A (is) Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, sem inniheldur búdesóníð
SE8300495D0 (sv) Improvements in or relating to nasal pharmaceutical compositions
TH51990B (th) การปล่อยสารออกฤทธิ์ที่เป็นผงแห้ง
TH51990A3 (th) การปล่อยสารออกฤทธิ์ที่เป็นผงแห้ง